1. Taiwan Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Genetics Generation Advancement Corp.

Genetics Generation Advancement Corp.

TTPEX:4160
37.25
TWD
-0.15
(-0.40%)
0.69EPS
55.64P/E
1.02BMarket Cap
Genetics Generation Advancement Corp.
TPEX:4160
(Taipei Exchange)

Recent

price

37.25

P/E

ratio

55.64

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
8.96
8.8
11.25
9.04
8.39
10.37
12.96
13.7
14.3
16.09
16.6
19.46
20.52
22.2
24.8
22.6
23.48
Revenue per Share
0.71
0.75
-0.75
-1.26
-1.58
-0.49
-0.32
0.41
0.63
0.69
-0.59
0.29
0.96
1.07
2.05
0.8
0.69
Basic EPS, GAAP
-1.28
-0.86
-1.75
-3.53
0.81
-1.02
-0.57
0.01
-0.23
-0.23
0.24
-0.12
1.64
2.31
2.08
-1.86
-1.53
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
0.37
0.57
0.62
- -
0.26
0.43
0.48
1.85
- -
Dividend per Share
9.33
13.61
14.94
13.74
12.16
11.69
11.36
11.77
12.08
12.93
11.7
11.95
13.02
16.11
20.72
22.54
18.47
Book Value per Share
9.33
13.17
14.53
13.32
11.76
11.29
10.96
11.14
11.47
12.24
10.66
10.96
12.12
15.28
19.99
21.64
17.57
Tangible Book Value per Share
9
20
24
26
26
26
27
27
27
27
27
27
27
27
27
27
26
Basic Weighted Avg Shares
78
175
267
236
222
275
346
366
382
429
443
520
548
593
662
603
614
Sales/Revenue/Turnover
1.06
5.56
-10.59
-24.19
-14.66
-6.15
-3.07
2.67
3.06
2.67
-4.81
-0.87
3.81
3.02
7.48
2.12
0.41
Operating Margin (%)
1
4
4
11
4
4
5
5
5
5
7
10
11
15
18
25
31
Depreciation Expense
6
15
-18
-33
-42
-13
-8
11
17
18
-16
8
26
29
55
21
18
Net Income, GAAP
49.67
30.44
- -
- -
- -
- -
- -
12.18
6.44
11.75
- -
21.47
21.82
17.19
18.59
21.74
6.5
Effective Tax Rate (%)
7.98
8.55
-6.65
-13.89
-18.87
-4.69
-2.44
2.98
4.42
4.26
-3.54
1.51
4.7
4.82
8.26
3.54
2.92
Profit Margin (%)
80
264
349
310
108
246
246
264
272
298
249
255
293
302
391
419
311
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
2
10
2
5
17
LT Debt
97
295
382
346
322
312
303
313
322
344
312
319
347
430
553
602
494
Total Equity
0.62
3.35
- -
- -
- -
- -
- -
2.69
3.33
2.93
- -
-1.11
4.69
3.69
7.41
1.44
0.26
Return on Invested Capital (%)
16.51
10.71
- -
- -
- -
- -
- -
3.72
5.19
5.35
- -
2.39
7.62
6.92
10.23
3.41
3.49
Return on Capital (%)
8.85
7.17
-5.09
-8.75
-12.22
-4.07
-2.74
3.53
5.3
5.48
-4.78
2.48
7.72
7.35
11.13
3.7
3.71
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
75
93
110
LT Borrowings
- -
- -
- -
LT Finance Leases
5
4
17
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
27
27
Market Capitalization
1,267
1,127
1,018

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
618
552
518
Cash, Cash Equivalents & STI
409
353
321
Accounts Receivable, Net
109
98
107
Inventories
71
67
58
Total Current Liabilities
199
222
208
Payables & Accruals
- -
- -
- -
ST Debt
75
93
110
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.33%
14.49%
8.76%
Free Cash Flow
-461.61%
-362.61%
-189.27%
Net Income, GAAP
-26.68%
23.98%
-60.93%
Sales/Revenue/Turnover
8.54%
6.74%
-8.88%
Total Cash Common Dividend
- -
- -
283.58%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
167
170
170
155
662
2025
143
145
145
169
603
2026
149
150
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.53
0.68
0.72
0.11
2.05
2025
0.29
0.08
0.02
0.39
0.8
2026
0.01
0.23
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.48
2025
- -
- -
- -
- -
1.85
2026
- -
- -
- -
- -
- -
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Genetics Generation Advancement Corp. (Ticker: 4160.TWO) engages in the research, development, and commercialization of genetic technologies focused on advancing human health and agricultural productivity. The company offers core products and services including gene editing tools such as CRISPR-based kits and reagents; custom genetic modification services for research institutions and biotech firms; proprietary gene therapy vectors for therapeutic applications; and high-throughput genomic sequencing platforms tailored for precision medicine and crop improvement. It operates primarily in the biotechnology sector, targeting pharmaceutical companies, academic researchers, agricultural enterprises, and healthcare providers across Asia-Pacific markets, with expanding presence in North America and Europe. Founded in 2015 and headquartered in Taipei, Taiwan, the company maintains subsidiaries in Singapore and the United States to support global R&D and manufacturing. In the past two years, Genetics Generation Advancement Corp. completed a strategic partnership with a leading Japanese pharmaceutical firm for co-developing oncology gene therapies; secured a TWD 500 million funding round in 2024 to accelerate its agricultural biotech division; launched a new suite of AI-enhanced gene design software in early 2025; and expanded operations through the acquisition of a U.S.-based CRISPR patent portfolio, marking a significant shift toward integrated therapeutic platforms.